OptraSCAN has received FDA 510(k) clearance for its OS-Ultra digital pathology scanner and will showcase the device at Pathology Visions 2026.
The company positions the system for laboratories moving from manual microscopy to digital workflows, where slides are scanned, stored and analyzed as images rather than glass.
Why scanners are the chokepoint
The shift to digital pathology depends first on hardware. Whole-slide imaging scans a physical specimen into a file precise enough for diagnosis, and throughput decides whether a lab can adopt digital reads at scale.
OptraSCAN already sells an open digital pathology platform built around a scalable scanner family. The clearance adds another option for labs weighing volume against cost.
A market in motion
The timing is notable. Agilent announced it is acquiring Proscia for up to $270M in the same week, a sign that larger players see pathology software as strategic ground.
Regulators have also tightened expectations around AI-adjacent tools. The FDA has warned device makers that retraining algorithms or moving them to the cloud can require fresh clearance.
For OptraSCAN, the challenge is standing out in a market where instrument giants and software vendors are converging. The clearance gives it a seat at the table, though the buying decisions will come down to scan quality, integration and price.
